Wells Fargo
INMB icon

Wells Fargo’s INmune Bio INMB Stock Holding History

Wells Fargo’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.17K Sell
2,555
-8,087
-76% -$11.2K ﹤0.01% 6252
2026
Q1 		$12K Sell
10,642
-14,215
-57% -$20.3K ﹤0.01% 5928
2025
Q4 		$38.8K Buy
24,857
+10,970
+79% +$19.6K ﹤0.01% 5632
2025
Q3 		$28.7K Buy
13,887
+4,204
+43% +$9.62K ﹤0.01% 5704
2025
Q2 		$22.4K Buy
9,683
+3,165
+49% +$23.2K ﹤0.01% 5766
2025
Q1 		$50.9K Buy
6,518
+141
+2% +$1.12K ﹤0.01% 5393
2024
Q4 		$29.8K Buy
6,377
+2,155
+51% +$11.2K ﹤0.01% 5648
2024
Q3 		$22.8K Buy
4,222
+259
+7% +$1.84K ﹤0.01% 5610
2024
Q2 		$35K Buy
3,963
+3,816
+2,596% +$37.6K ﹤0.01% 5420
2024
Q1 		$1.73K Buy
147
+2
+1% +$24 ﹤0.01% 6058
2023
Q4 		$1.63K Sell
145
-2,219
-94% -$18.6K ﹤0.01% 6134
2023
Q3 		$16K Sell
2,364
-865
-27% -$7.17K ﹤0.01% 5677
2023
Q2 		$29.3K Sell
3,229
-152
-4% -$1.22K ﹤0.01% 5622
2023
Q1 		$21.8K Sell
3,381
-4,222
-56% -$34K ﹤0.01% 5600
2022
Q4 		$48.2K Sell
7,603
-5,075
-40% -$36K ﹤0.01% 4877
2022
Q3 		$78K Sell
12,678
-949
-7% -$8.33K ﹤0.01% 4741
2022
Q2 		$121K Sell
13,627
-589
-4% -$4.38K ﹤0.01% 4537
2022
Q1 		$120K Buy
14,216
+2,707
+24% +$24.3K ﹤0.01% 5228
2021
Q4 		$118K Buy
11,509
+8,882
+338% +$131K ﹤0.01% 5544
2021
Q3 		$51K Buy
2,627
+2,575
+4,952% +$49.7K ﹤0.01% 5616
2021
Q2 		$1K Hold
52
– – ﹤0.01% 6674
2021
Q1 		$1K Buy
52
+12
+30% +$216 ﹤0.01% 6726
2020
Q4 		$1K Hold
40
– – ﹤0.01% 6351
2020
Q3 		$0 Buy
40
+17
+74% +$173 ﹤0.01% 6583
2020
Q2 		$0 Buy
23
+1
+5% +$5 ﹤0.01% 6530
2020
Q1 		$0 Buy
+22
New +$99 ﹤0.01% 6473

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's INMB Position: Q2 2026 in Review

Wells Fargo reduced its INmune Bio (INMB) stake by 76% in Q2 2026, selling an estimated $11.2K and leaving 2,555 shares worth $4.17K. The position accounts for ﹤0.01% of the portfolio, ranked #6252.

Wells Fargo first reported a position in INMB in Q1 2020 and has held it in 26 quarters since. The position peaked at $121K in Q2 2022. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Wells Fargo held 2,555 shares of INmune Bio worth $4.17K as of Q2 2026.
  • Wells Fargo sold 8,087 INmune Bio shares in Q2 2026, an estimated $11.2K.
  • INmune Bio made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6252 holding.
  • Wells Fargo first reported a position in INmune Bio in Q1 2020 and has held it in 26 quarters since.
  • Wells Fargo's INmune Bio position peaked at $121K in Q2 2022.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.